Innovating to provide a competitive edge to our big pharma clients in the development of super specialty novel therapies.
A major pharmaceutical company wanted to accelerate the development of a novel therapy line and identify where and how it can differentiate its early stage assets.
We did an end-to-end mapping of clinical and pre-clinical activities and a deep dive across the scientific ecosystem. Our capabilities allowed us to screen public data for key assets, existing capabilities, pipelines and resources in the innovation ecosystem.
We could identify early stage assets by landscaping competitor activities and related developments. This helped us anticipate competitor strategy and identify key opportunities and possible risks to our programs.
We then extracted development information from scientific studies, clinical and pre-clinical activities and, key research and market information from public data.
We used network analysis to identify peripheral capabilities that can be leveraged for innovation.
We used proprietary algorithms to collect and assimilate data from specialized public databases. Leveraging Ontologies, the datasets were normalized and were given a frame of reference with respect to the development target.
Further, processing was done using network analysis algorithms to study momentum of IP as well as potential hotspots for exploratory innovation. This enabled the client to make informed decisions, minimize risks and identify niche opportunities.